Dulaglutide and Semaglutide are both GLP-1 receptor agonists, primarily studied for their roles in managing Type 2 Diabetes Mellitus. Evidence suggests that Dulaglutide has been associated with a significant reduction in stroke risk in T2DM patients. Semaglutide, on the other hand, has shown a notable reduction in cardiovascular mortality in T2DM patients. Both peptides are part of a class of medications that are increasingly being recognized for benefits extending beyond glycemic control, including cardiovascular protection. The corpus includes a substantial number of studies for both, with Semaglutide having a considerably larger body of research indexed.
| Dulaglutide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 40 | 691 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | cohort · 1 rct · 15 review · 3 meta analysis · 6 other · 7 | rct · 67 meta analysis · 9 review · 23 in vitro · 4 cohort · 16 preclinical animal · 4 case report · 3 case series · 3 other · 26 |
| Studies with explicit sample size | 6 | 42 |
| Head-to-head studies in corpus | 8 | |
Studies in our corpus that mention both Dulaglutide and Semaglutide — the gold-standard direct comparison evidence.
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These robust findings strongly support the exp…
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently causes less discomfort, it could signif…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type 2 Diabetes. The findings will provide va…
This comparative review is crucial for clinicians and patients in making informed treatment decisions, highlighting the distinct strengths of each medication. The findings underscore Tirzepatide's potent efficacy in weight management and glycemic control, p…
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clinicians and researchers should recognize …
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obesity alongside IBD, understanding which …
No direct head-to-head trials in our corpus. Indirect comparison only. While both are GLP-1 receptor agonists, a network meta-analysis found that Dulaglutide reduced stroke risk by 23% (RR: 0.77), whereas Semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients. Semaglutide has also been investigated for its potential link to non-arteritic anterior ischemic optic neuropathy risk, and oral semaglutide 25 mg has shown equivalent exposure to subcutaneous 2.4 mg, leading to greater weight loss in simulated studies. The corpus contains significantly more studies on Semaglutide (729) compared to Dulaglutide (42), suggesting a broader range of research and potentially more extensive data available for Semaglutide, including investigations into areas like Parkinson's disease and combination with exercise for weight loss. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been shown to offer superior glycemic control and weight loss compared to Dulaglutide in meta-analyses.
Looking for vendor-level purity, endotoxin, and HPLC data on Dulaglutide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.